Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)

• Egile Nagusiak: N. Yu. Velts (Egilea), O. V. Velts (Egilea), R. N. Alyautdin (Egilea)
• Formatua: Liburua
• Argitaratua: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2024-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect, which is a severe adverse drug reaction (ADR)...